Palvella Therapeutics, Inc. Operating Lease Cost
Palvella Therapeutics, Inc. (PVLA) reported Operating Lease Cost of $61.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-31
- Palvella Therapeutics, Inc. operating lease, cost for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, cost for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, cost for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, cost for the quarter ending 2023-12-31 was $307.00K, a 25.67% decline year-over-year.
- Palvella Therapeutics, Inc. operating lease, cost for fiscal 2025 was $61.00K.
- Palvella Therapeutics, Inc. operating lease, cost for fiscal 2023 was $1.17M, a 13.79% decline from fiscal 2022.
- Palvella Therapeutics, Inc. operating lease, cost for fiscal 2022 was $1.36M, a 8.56% decline from fiscal 2021.
- Palvella Therapeutics, Inc. operating lease, cost for fiscal 2021 was $1.48M, a 1.72% decline from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $61.00K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $307.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $307.00K derived: sum of 3 quarters · filed 2024-08-14 | $587.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $307.00K derived: sum of 2 quarters · filed 2024-05-15 | $587.00K derived: sum of 3 quarters · filed 2024-11-13 | $874.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $307.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $587.00K derived: sum of 2 quarters · filed 2024-11-13 | $874.00K derived: sum of 3 quarters · filed 2024-11-13 | $1.17M 10-K · filed 2024-03-29 |
| 2023-09-30 | $280.00K 10-Q · filed 2024-11-13 | $567.00K derived: sum of 2 quarters · filed 2024-11-13 | $862.00K 10-Q · filed 2024-11-13 | $1.27M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $287.00K 10-Q · filed 2024-08-14 | $574.00K 10-Q · filed 2024-08-14 | $988.00K derived: sum of 3 quarters · filed 2024-08-14 | $1.30M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $288.00K 10-Q · filed 2024-05-15 | $701.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.01M derived: sum of 3 quarters · filed 2024-05-15 | $1.35M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $413.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $727.00K derived: sum of 2 quarters · filed 2024-03-29 | $1.06M derived: sum of 3 quarters · filed 2024-03-29 | $1.36M 10-K · filed 2024-03-29 |
| 2022-09-30 | $314.00K 10-Q · filed 2023-11-14 | $645.00K derived: sum of 2 quarters · filed 2023-11-14 | $943.00K 10-Q · filed 2023-11-14 | $1.35M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $331.00K 10-Q · filed 2023-08-10 | $680.00K 10-Q · filed 2023-08-10 | $1.04M derived: sum of 3 quarters · filed 2023-08-10 | $1.41M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $349.00K 10-Q · filed 2023-05-11 | $706.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.08M derived: sum of 3 quarters · filed 2023-05-11 | $1.46M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $727.00K derived: sum of 2 quarters · filed 2023-03-31 | $1.11M derived: sum of 3 quarters · filed 2023-03-31 | $1.48M 10-K · filed 2023-03-31 |
| 2021-09-30 | $370.00K 10-Q · filed 2022-11-04 | $749.00K derived: sum of 2 quarters · filed 2022-11-04 | $1.13M 10-Q · filed 2022-11-04 | $1.50M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $379.00K 10-Q · filed 2022-08-04 | $744.00K 10-Q · filed 2021-08-05 | $1.13M derived: sum of 3 quarters · filed 2022-08-04 | $1.49M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $377.00K 10-Q · filed 2022-05-11 | $752.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.11M derived: sum of 3 quarters · filed 2022-05-11 | $1.46M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $735.00K derived: sum of 2 quarters · filed 2022-03-02 | $1.08M derived: sum of 3 quarters · filed 2022-03-02 | $1.51M 10-K · filed 2022-03-02 |
| 2020-09-30 | $360.00K 10-Q · filed 2021-11-02 | $707.00K derived: sum of 2 quarters · filed 2021-11-02 | $1.13M 10-Q · filed 2021-11-02 | $1.57M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $347.00K 10-Q · filed 2021-08-05 | $751.00K 10-Q · filed 2021-08-05 | $1.22M derived: sum of 3 quarters · filed 2021-08-05 | $1.63M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $404.00K 10-Q · filed 2021-05-17 | $868.00K derived: sum of 2 quarters · filed 2021-05-17 | $1.29M derived: sum of 3 quarters · filed 2021-05-17 | $1.71M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $464.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $883.00K derived: sum of 2 quarters · filed 2021-03-31 | $1.31M derived: sum of 3 quarters · filed 2021-03-31 | $1.52M 10-K · filed 2021-03-31 |
| 2019-09-30 | $419.00K 10-Q · filed 2020-11-04 | $842.00K derived: sum of 2 quarters · filed 2020-11-04 | $1.06M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $423.00K 10-Q · filed 2020-08-10 | $646.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $224.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |